Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05518149 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)

Study acronym: VENTURA-LT
StatusTerminated
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Results posted: Oct 6, 2026 Lead sponsor: Janssen Research & Development, LLC to Janssen Research & Development, LLC · Sponsor's reason: The study was Early Terminated as per Sponsor's decision (communicated to sites on 06Mar2025) to The study was Early Terminated as per Sponsor's decision (communicated to sites on 06Mar2025) · Eligibility criteria expanded, about 9 words · 2 more Show 5 more changesShow less
    • Lead sponsor: Janssen Research & Development, LLC to Janssen Research & Development, LLC
    • Sponsor's reason: The study was Early Terminated as per Sponsor's decision (communicated to sites on 06Mar2025) to The study was Early Terminated as per Sponsor's decision (communicated to sites on 06Mar2025)
    • Eligibility criteria expanded, about 9 words
    • Secondary endpoints: details revised at 6 of 6 entries
    • Site details revised at 7 of 234 sites
  2. Re-verified, no change to tracked fieldsv41
  3. Primary endpoints: 10 to 25 Secondary endpoints revised (6)v40 Show 1 more changeShow less
    • Secondary endpoints revised (6)

    See this version in full on ClinicalTrials.gov ↗

  4. Trial status: Active, Not Recruiting to Terminated Sponsor's reason: The study was Early Terminated as per Sponsor's decision (communicated to sites on 06Mar2025) Enrollment target: estimated 840 to confirmed 871 · Study sites: 224 to 234 · Primary completion date changed from estimate of Apr 11, 2025 to Apr 25, 2025 · 1 morev39 Show 4 more changesShow less
    • Enrollment target: estimated 840 to confirmed 871
    • Study sites: 224 to 234
    • Primary completion date changed from estimate of Apr 11, 2025 to Apr 25, 2025
    • Study completion date changed from estimate of Apr 25, 2025 to May 8, 2025
  5. Re-verified, no change to tracked fieldsv38
Show 36 earlier versionsHide 36 earlier versions
  1. Study sites: 222 to 224v37
  2. Trial status: Recruiting to Active, Not Recruiting Primary completion date: Oct 22, 2025 to Apr 11, 2025 · Completion date: Dec 15, 2025 to Apr 25, 2025 · Study sites revised (222)v36 Show 3 more changesShow less
    • Primary completion date: Oct 22, 2025 to Apr 11, 2025
    • Completion date: Dec 15, 2025 to Apr 25, 2025
    • Study sites revised (222)

    See this version in full on ClinicalTrials.gov ↗

  3. Study sites: 219 to 222v35
  4. Study sites: 204 to 219v34
  5. Re-verified, no change to tracked fieldsv33
  6. Study sites: 196 to 204v32
  7. Re-verified, no change to tracked fieldsv31
  8. Study sites: 192 to 196v30
  9. Re-verified, no change to tracked fieldsv29
  10. Study sites: 188 to 192v28
  11. Study sites: 185 to 188 Completion date: Oct 22, 2025 to Dec 15, 2025v27 Show 1 more changeShow less
    • Completion date: Oct 22, 2025 to Dec 15, 2025
  12. Study sites: 179 to 185v26
  13. Study sites: 169 to 179v25
  14. Study sites: 163 to 169v24
  15. Study sites: 150 to 163v23
  16. Study sites: 143 to 150v22
  17. Study sites: 123 to 143v21
  18. Study sites: 107 to 123v20
  19. Study sites: 98 to 107v19
  20. Study sites: 84 to 98v18
  21. Study sites: 68 to 84v17
  22. Study sites: 60 to 68v16
  23. Study sites: 53 to 60v15
  24. Study sites: 42 to 53v14
  25. Study sites: 38 to 42v13
  26. Study sites: 28 to 38v12
  27. Study sites: 24 to 28v11
  28. Study sites: 20 to 24 Completion date: Oct 25, 2025 to Oct 22, 2025v10 Show 1 more changeShow less
    • Completion date: Oct 25, 2025 to Oct 22, 2025
  29. Study sites: 16 to 20v9
  30. Study sites: 13 to 16v8
  31. Study sites: 311 to 13v7
  32. Primary endpoints: 9 to 10 Study sites: 297 to 311 · Completion date: Oct 24, 2025 to Oct 25, 2025 · Secondary endpoints: details revised at 1 of 6 entries · 1 morev6 Show 4 more changesShow less
    • Study sites: 297 to 311
    • Completion date: Oct 24, 2025 to Oct 25, 2025
    • Secondary endpoints: details revised at 1 of 6 entries
    • Eligibility criteria expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  33. Study sites: 272 to 297 Completion date: Oct 22, 2025 to Oct 24, 2025v5 Show 1 more changeShow less
    • Completion date: Oct 22, 2025 to Oct 24, 2025
  34. Study sites: 255 to 272v4
  35. Trial status: Not Yet Recruiting to Recruiting Primary endpoints revised (9) · Enrollment target: 960 to 840 · Study sites: 157 to 255 · 2 morev3 Show 5 more changesShow less
    • Primary endpoints revised (9)
    • Enrollment target: 960 to 840
    • Study sites: 157 to 255
    • Start date changed from estimate of Sep 9, 2022 to Sep 22, 2022
    • Eligibility criteria expanded, about 16 words

    See this version in full on ClinicalTrials.gov ↗

  36. Study sites: 151 to 157v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Johnson & Johnson
289 trials monitored
See 17 trials at risk
Depression
2,998 trials monitored
See 166 trials at risk
The purpose of this study is to assess the long-term safety and tolerability of aticaprant administered as adjunctive therapy to a current antidepressant (selective serotonin reuptake inhibitor \[SSRI\] or serotonin and norepinephrine reuptake inhibitor \[SNRI\]) in all participants with major depressive disorder (MDD).
Trial Details
NCT Number NCT05518149
Lead Sponsor Janssen Research & Development, LLC
Conditions Depressive Disorder, Major
Enrollment 871 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov